17/01/2016
Attention! Notice to my 3rd year Pharmacology students:
1. This assignment covers Chapters 39-42.
2. Please write legibly. If I can’t read them, I won’t give any points.
3. If I catch anyone writing for somebody else (again!), both of these students will not get any credit for the class standing.
4. Deadline for submission: January 30, 2016.
5. For January 23, read Chapters 31-34
6. For January 30, read Chapters 35-38
7. Coverage for the midterms: Chapters 17-34 and 39-42
8. Lastly, I will not tolerate anymore anyone reading their books while reciting in my class. I want to make sure the points I give are worth it. If anyone would insist on reading, I will give 0.
**************************************************************************
1. What is the MOA of GCs*?
2. What are the physiologic effects of GCs?
3. Why GCs have been associated with the development of PUD**?
4. Differentiate the treatment between acute & chronic adrenocortical insufficiency.
5. Explain the use of GCs in diagnostic purposes.
6. Enumerate the therapeutic indications for the use of GCs in non adrenal disorders?
7. What are the toxicities of GCs?
8. What are the C/I*** & precautions to the use of GCs?
9. What are the conditions that would result from excessive production of aldosterone due to tumors?
10. Discuss the MOA, clinical indications & adverse reactions of the following:
a. Aminoglutethemide
b. Ketoconazole
c. Metyrapone
d. Trilostane
e. Abiraterone
f. Mifepristone
g. Mitotane
11. Discuss the conditions associated with the disturbances in ovarian functions.
12. Explain the MOA, clinical uses, adverse effects & C/I to the use of the following:
a. Estrogens
b. Progestins
c. Hormonal contraception
d. Clomiphene
e. Androgens & anabolic steroids
13. Discuss the chemical contraception in men.
14. Differentiate type 1 and type 2 diabetes.
15. Discuss insulin and the 4 types of insulin preparations.
16. What are the complications of insulin treatment?
17. Discuss the following:
a. 1st generation sulfonylureas
b. 2nd generation sulfonylureas
18. Explain the MOA, clinical uses & toxicities of the following:
a. Biguanides
b. Thiazolidinediones
c. Alpha-gluconidase inhibitor
d. Dipeptidyl peptidase-4 (DPP-4) inhibitprs
e. glucagon
19. Discuss the combination treatment in Diabetes Mellitus.
20. Explain how do the following regulate bone mineral homeostasis:
a. PTH
b. Vitamin D
c. Fibroblast growth factor 23
d. Interaction of PTH, vitamin D and fibroblast growth factor 23
e. Calcitonin
f. Estrogens
21. How do the following affect bone mineral homeostasis?
a. Biphosphonates
b. Thiazide diuretics
c. Fluoride
Legend:
* GCs – glucocorticoids
** PUD – peptic ulcer disease
*** C/I - contraindications